Dongyang Sunshine Pharmaceutical (06887) announced that on January 26, 2026, the company entered into a strategic cooperation agreement with Shenzhen Crystal Technology Co., Ltd. (Shenzhen Crystal). Under the strategic cooperation agreement, the two parties plan to establish a joint venture to build an AI-driven drug discovery platform, focusing on the following areas of collaboration:
According to a report by Zhitong Finance, Dongyang Pharmaceuticals (06887) announced that the company entered into a strategic cooperation agreement with Shenzhen XtalPi Technology Co., Ltd. (Shenzhen XtalPi) on January 26, 2026. Under the strategic cooperation agreement, both parties plan to establish a joint venture to jointly build an AI-driven drug discovery platform, focusing on the following areas of collaboration:
(1) Establishment of a joint laboratory for co-development of innovative drug pipelines
Both parties will jointly establish a joint laboratory with the aim of AI-driven automation. Relying on Shenzhen XtalPi’s automated experimental platform technology and deployment experience, they will achieve a closed-loop R&D process encompassing 'design-build-test-learn,' focusing on autoimmune diseases to jointly discover candidate drugs, which will be advanced by the joint venture.
(2) Joint development and promotion of large-scale models
Based on the company’s high-quality preclinical data across multiple targets, combined with Shenzhen XtalPi’s AI algorithm platform and large model training capabilities, the two parties will develop a PB-PK prediction large model that aligns with industry-leading commercial software and jointly build an AI-powered drug discovery engine covering the entire lifecycle of drug research and development.
Leveraging Shenzhen XtalPi’s global commercial network and experience in productizing AI platforms, they will promote the group’s independently developed 'HEC-SynAI Drug Synthesis Large Model,' 'HEC-PharmAI Formulation Large Model,' and a next-generation PB-PK large model.
(3) Creation of a 'Model as a Service' (MaaS) business model
The two parties plan to jointly build an AI supercomputing platform based on the 'computing power support + data development + ecosystem sharing' model. They will open their collaborative achievements to academia and the industry, transforming data assets and AI products into a 'Model as a Service' (MaaS) business model.
The board believes that the strategic cooperation agreement provides a valuable opportunity for the contracting parties to leverage their respective resources and expertise to create mutual benefits and synergies. Therefore, the board considers that entering into the strategic cooperation agreement is in the best interests of the company and its shareholders.
